The growing problem of benign connective tissue tumours

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages 879-880

  Thomas, David M ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; EMACTUZUMAB; PROTEIN COL6A3; PROTEIN CSF1; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

BENIGN TUMOR; CANCER INCIDENCE; CHRONIC DISEASE; CONNECTIVE TISSUE TUMOR; DRUG EFFICACY; DRUG TOLERABILITY; FETUS DEVELOPMENT; FIBROMATOSIS; GIANT CELL TUMOR; HUMAN; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; NOTE; OSTEOCLASTOMA; PATIENT DECISION MAKING; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TENOSYNOVIAL GIANT CELL TUMOR; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; FEMALE; GIANT CELL TUMORS; MALE; SOFT TISSUE NEOPLASMS; SYNOVITIS, PIGMENTED VILLONODULAR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GIANT CELL TUMORS; HUMANS; MALE; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SOFT TISSUE NEOPLASMS; SYNOVITIS, PIGMENTED VILLONODULAR;

EID: 84938203295     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00147-3     Document Type: Note

References (6)

1. Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011, 47:2493-2511.
2. Myhre-Jensen O A consecutive 7-year series of 1331 benign soft tissue tumours. Clinicopathologic data. Comparison with sarcomas. Acta Orthop Scand 1981, 52:287-293.
3. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013, 14:901-908.
4. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
5. Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015, published online July 13. http://dx.doi.org/10.1016/S1470-2045(15)00132-1.
6. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006, 103:690-695.